Dermira Announces Proposed Public Offering of Common Stock
March 18 2019 - 3:30PM
Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated
to bringing biotech ingenuity to medical dermatology by delivering
differentiated, new therapies to the millions of patients living
with chronic skin conditions, today announced that it intends to
offer $110.0 million of its common stock in an underwritten public
offering. Dermira also expects to grant to the underwriters a
30-day option to purchase up to an additional $16.5 million of its
common stock in the offering. All of the shares will be offered and
sold by Dermira. The offering is subject to market and other
conditions, and there can be no assurance as to whether or when the
offering may be completed, or as to the actual size or terms of the
offering.
Citigroup, Cowen, Cantor Fitzgerald & Co. and
Guggenheim Securities are acting as book-runners for the offering.
Needham & Company and H.C. Wainwright & Co. are acting as
co-managers.
The public offering will be made pursuant to a
shelf registration statement on Form S-3 that was filed by Dermira
with the Securities and Exchange Commission (“SEC”) on November 7,
2018 and was declared effective on November 21, 2018. A preliminary
prospectus supplement and accompanying prospectus relating to and
describing the terms of the offering will be filed with the SEC and
will be available on the SEC’s website at www.sec.gov. When
available, copies of the preliminary prospectus supplement and
accompanying prospectus may be obtained from Citigroup Global
Markets Inc., c/o Broadridge Financial Solutions, Attention:
Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717,
or by telephone at 800-831-9146; Cowen and Company, LLC, c/o
Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood,
NY 11717, or by telephone at 631-274-2806; Cantor Fitzgerald &
Co., Attention: Capital Markets, 499 Park Avenue, 6th Floor, New
York, NY 10022, or by email at prospectus@cantor.com; and
Guggenheim Securities, LLC, Attention: Equity Syndicate Department,
330 Madison Avenue, 8th Floor, New York, NY 10017, by telephone at
212-518-9658, or by email at
GSEquityProspectusDelivery@guggenheimpartners.com.
This press release shall not constitute an offer to
sell or a solicitation of an offer to buy Dermira’s common stock,
nor shall there be any sale of Dermira’s common stock in any state
or jurisdiction in which such an offer, solicitation or sale would
be unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction.
Forward-Looking Statements
The information in this press release contains
forward-looking statements and information within the meaning of
Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended, which are
subject to the “safe harbor” created by those sections. This press
release contains forward-looking statements that involve
substantial risks and uncertainties, including statements regarding
the Dermira’s intention to conduct an offering of its shares of
common stock. These statements deal with future events and involve
known and unknown risks, uncertainties and other factors that may
cause our achievements to be materially different from the
information expressed or implied by these forward-looking
statements. For a discussion of important factors that may cause
our actual achievements to differ materially from those expressed
or implied by Dermira’s forward-looking statements, you should
refer to the section entitled “Risk Factors” set forth in Dermira’s
Annual Report on Form 10-K and other filings Dermira makes with
the SEC from time to time. Furthermore, such
forward-looking statements speak only as of the date of this press
release. We undertake no obligation to publicly update any
forward-looking statements or reasons why actual results might
differ, whether as a result of new information, future events or
otherwise, except as required by law.
Contacts:
Media:Erica JeffersonVice President, Corporate
Communications650-421-7216media@dermira.com
Investors:Ian Clements, Ph.D.Vice President,
Investor Relations650-422-7753investor@dermira.com
Journey Medical (NASDAQ:DERM)
Historical Stock Chart
From Jun 2024 to Jul 2024
Journey Medical (NASDAQ:DERM)
Historical Stock Chart
From Jul 2023 to Jul 2024